Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 5/14/24 → 5/14/26 |
Funding
- Genentech Inc: $2.00
23-GI-132-GI (GO44479): A Phase II, Open-Label, Mulitcenter, Randomized Study of The Efficacy and Safety of Adjuvant Autogene Cevumeranplus Atezolizumab and mFOLFIRINOX Vs mFOLFIRINOX Alone in Patients with Resected Pancreatic Ductal Adenocarcinoma
- Kim, Joseph (PI)